fenobam

 

Topic mentions per year

Topic mentions per year

1982-2017
024619822017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Cognitive deficits in fragile X syndrome (FXS) are attributed to molecular abnormalities of the brain's vast and heterogeneous… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Amantadine, an N-methyl-D-aspartate glutamate receptor antagonist, is currently the only pharmacological treatment for levodopa… (More)
Is this relevant?
2011
2011
BACKGROUND The metabotropic glutamate receptor 5 noncompetitive antagonist fenobam is analgesic in rodents. Future development of… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
L-DOPA remains the gold-standard treatment for Parkinson's disease but causes motor fluctuations and dyskinesia. Metabotropic… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE A pilot open label, single dose trial of fenobam, an mGluR5 antagonist, was conducted to provide an initial evaluation… (More)
  • figure 1
  • figure 2
Is this relevant?
2009
2009
Metabotropic glutamate receptor subtype 5 (mGlu5) has been demonstrated to play a role in the modulation of numerous nociceptive… (More)
  • table 1
  • table 2
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
2009
2009
Fenobam [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea] was suggested to possess anxiolytic actions 30… (More)
Is this relevant?
2007
2007
Optimization of affinity and microsomal stability led to identification of the potent, metabolically stable fenobam analog 4l… (More)
Is this relevant?
2006
2006
Fenobam (1) was developed by McNeil Laboratories as an anxiolytic agent with an unknown molecular target in the late 1970s. In a… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Fenobam [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea] is an atypical anxiolytic agent with unknown… (More)
  • figure 1
  • figure 2
  • table 2
  • figure 3
  • figure 4
Is this relevant?